Zoetis (ZTS) Total Non-Current Liabilities (2012 - 2026)
Zoetis' (ZTS) quarterly Total Non-Current Liabilities came in at $11.6 billion in Q1 2026, up 26.99% year-on-year from $9.2 billion in Q1 2025, and down 1.56% on a QoQ basis from $11.8 billion in Q4 2025.
Zoetis (ZTS) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Total Non-Current Liabilities data on file, last reported at $11.6 billion in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 26.99% year-over-year to $11.6 billion in Q1 2026; TTM through Mar 2026 was $11.6 billion, a 26.99% increase from a year earlier, with the FY2025 full-year figure at $11.8 billion, up 28.6% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $11.6 billion, down from $11.8 billion in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ZTS reached as high as $11.8 billion in Q4 2025 and fell as low as $8.8 billion in Q3 2022.
- Historically, Total Non-Current Liabilities has averaged $9.4 billion across 5 years, with a median of $9.1 billion in 2023.
- Across the five-year window, Total Non-Current Liabilities fell 11.75% in 2023 and gained 28.6% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $10.3 billion in 2022, then fell by 11.75% to $9.1 billion in 2023, then advanced by 1.51% to $9.2 billion in 2024, then climbed by 28.6% to $11.8 billion in 2025, then dropped by 1.56% to $11.6 billion in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $11.6 billion in Q1 2026, $11.8 billion in Q4 2025, and $9.5 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 604.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.64 Bn |
| Dec 31, 2025 | 11.83 Bn |
| Sep 30, 2025 | 9.50 Bn |
| Jun 30, 2025 | 9.23 Bn |
| Mar 31, 2025 | 9.17 Bn |
| Dec 31, 2024 | 9.20 Bn |
| Sep 30, 2024 | 8.85 Bn |
| Jun 30, 2024 | 8.98 Bn |
| Mar 31, 2024 | 9.07 Bn |
| Dec 31, 2023 | 9.06 Bn |
| Sep 30, 2023 | 8.77 Bn |
| Jun 30, 2023 | 8.91 Bn |
| Mar 31, 2023 | 9.05 Bn |
| Dec 31, 2022 | 10.26 Bn |
| Sep 30, 2022 | 8.77 Bn |
| Jun 30, 2022 | 8.96 Bn |
| Mar 31, 2022 | 8.96 Bn |
| Dec 31, 2021 | 9.12 Bn |
| Sep 30, 2021 | 8.77 Bn |
| Jun 30, 2021 | 9.46 Bn |